InVivoMAb anti-human/rat/fish AChR

Zhang L, Shen H, Gong Y, et al. Development of a dual-functional conjugate of antigenic peptide and Fc-III mimetics (DCAF) for targeted antibody blocking. Chem Sci. 2019,10(11):3271-3280. doi: 10.1039/c8sc05273e

Luo J, Lindstrom J. Antigen-specific immunotherapeutic vaccine for experimental autoimmune myasthenia gravis. J Immunol. 2014,193(10):5044-55. doi: 10.4049/jimmunol.1401392

Park JY, Mott M, Williams T, et al. A single mutation in the acetylcholine receptor δ-subunit causes distinct effects in two types of neuromuscular synapses. J Neurosci. 2014,34(31):10211-8. doi: 10.1523/JNEUROSCI.0426-14.2014

Chamberlain-Banoub J, Neal JW, Mizuno M, et al. Complement membrane attack is required for endplate damage and clinical disease in passive experimental myasthenia gravis in Lewis rats. Clin Exp Immunol. 2006,146(2):278-86.

Losen M, Stassen MH, Martínez-Martínez P, et al. Increased expression of rapsyn in muscles prevents acetylcholine receptor loss in experimental autoimmune myasthenia gravis. Brain. 2005,128(Pt 10):2327-37.

Poëa-Guyon S, Christadoss P, Le Panse R, et al. Effects of cytokines on acetylcholine receptor expression: implications for myasthenia gravis. J Immunol. 2005,174(10):5941-9.